@entity61206 ( @entity15796 ) is a new cytotoxic derivative of @entity2592 with improved cytotoxic activity and stability against deamination. Its pharmacokinetics were studied in @entity19 . The drug was administered intravenously and orally to ICR @entity19 to assess its pharmacokinetic parameters in plasma and whole blood. The lipophilic drug was administered in small unilamellar liposomes 100-400 nm in diameter. The concentrations of @entity15796 in plasma and erythrocytes were determined by high-performance liquid chromatography (HPLC). When given orally a rather low amount of the delivered @entity15796 was absorbed as the unchanged drug, resulting in a bioavailability of 1.1% from the plasma and 12.9% from whole blood. As shown elsewhere, the amount of drug absorbed is sufficient to provide excellent cytotoxic activity in the @entity11748 and in @entity1 xenograft models after oral administration. The mean residence time of @entity15796 after intravenous administration was 3.5 h in plasma and 6 h in whole blood giving @entity15796 a terminal half-life in blood substantially longer than that of @entity2592 . After oral administration the mean residence time was 18 h in plasma and whole blood. In summary, @entity15796 has a prolonged half-life after intravenous administration compared with @entity2592 . The distribution of @entity15796 in blood is highly dependent on its mode of administration.

Pharmacokinetics of XXXX in plasma and whole blood after intravenous and oral administration to @entity19 .

@entity1 :: ('9606', 'Species') :: ['human'] @entity61206 :: ('MESH:C098086', 'Chemical') :: ['N4-octadecyl-1-beta-D-arabinofuranosylcytosine'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytosine arabinoside'] @entity11748 :: ('MESH:D007939', 'Disease') :: ['L1210 leukemia'] @entity15796 :: ('MESH:C065145', 'Chemical') :: ['NOAC']
@entity61206 :: (MESH:C098086,Chemical) :: ['N4-octadecyl-1-beta-D-arabinofuranosylcytosine']
